Core Viewpoint - Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the 13 cheapest Dividend Aristocrats to invest in, indicating its strong dividend history and potential value in the market [1]. Financial Performance - For fiscal Q1 2026, the company reported revenue of $5.3 billion, reflecting a 0.4% overall growth and a 2.5% growth within the New BD segment [4]. - Adjusted gross margin increased to 53.4%, and adjusted EPS was reported at $2.91, both exceeding internal forecasts [4]. Strategic Developments - The company is set to finalize the combination of its Life Sciences unit with Waters Corporation through a Reverse Morris Trust transaction, which is expected to generate a $4 billion cash distribution [5]. - Of the $4 billion, $2 billion is earmarked for share repurchases and the remaining $2 billion for debt reduction, aligning with BD's focused capital allocation strategy [5]. - CEO Thomas Polen introduced a strategic agenda called "Excellence Unleashed," aimed at enhancing competitiveness, accelerating innovation, and ensuring consistent execution [6]. Leadership Changes - During the earnings call, CEO Thomas Polen announced Shawn Bevec as the new Senior Vice President of Investor Relations, indicating a focus on strengthening investor communications [3]. Market Position - Becton, Dickinson operates as a global medical technology company, providing medical supplies, devices, laboratory equipment, and diagnostic products to various healthcare sectors [7].

Financial Data and Key Metrics Changes - In FY 2025, the company achieved record revenue of $21.8 billion, representing a growth of 7.7% adjusted for foreign exchange and 2.9% organic growth [4] - Adjusted gross margin increased by 140 basis points, contributing to an 80 basis points expansion in adjusted operating margin, reaching a record 25% [5][8] - Adjusted diluted EPS grew by 9.6%, inclusive of tariffs, while the company returned $2.2 billion to shareholders, including a $1 billion share buyback [5] Business Line Data and Key Metrics Changes - The new BD delivered organic revenue growth of 3.9%, with solid growth across key platforms [4] - The company launched over 125 new products and added $1.3 billion through more than 20 accretive high-growth tuck-in acquisitions [6] Market Data and Key Metrics Changes - The company navigated a dynamic market environment, including changes in research spending, vaccine utilization, tariffs, and ongoing geopolitical uncertainty [8] - The agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corp is expected to create a life science and diagnostics leader, enhancing growth opportunities [9] Company Strategy and Development Direction - The company is transitioning to a new growth strategy called "Excellence Unleashed," focusing on three strategic priorities: compete, innovate, and deliver [10] - The strategy aims to enhance customer experience, leverage AI and robotics for innovation, and ensure operational excellence for consistent cash flow growth [10][11] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful culmination of the BD 2025 strategy, marking the most prolific growth period in the company's history [6] - The company expressed confidence in its ability to maximize shareholder value through strategic capital allocation and a focus on high-growth markets [9] Other Important Information - The company announced its 54th consecutive year of dividend increases, reinforcing its commitment to a reliable dividend policy [5] - The transaction with Waters Corp is expected to close on February 9, subject to customary closing conditions [9] Q&A Session Summary - No questions were received during the Q&A session, and the meeting concluded without any inquiries from shareholders [14]